Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study.

HIV clinical trials - 1 Nov 2016

Lake Jordan E, Seang Sophie, Kelesidis Theodoros, Currier Judith S, Yang Otto O

Abstract excerpt

BACKGROUND: Endothelial progenitor cells (EPCs) are bone marrow-derived cells that contribute to vascular repair. EPCs may be reduced in HIV-infected (HIV+) persons, contributing to cardiovascular disease (CVD). Telmisartan is an angiotensin receptor blocker that increases EPCs in HIV-uninfected adults. OBJECTIVE: To assess telmisartan's effects on EPC number and immunophenotype in older HIV + adults at risk for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin II Type 1 Receptor Blockers
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Benzoates

Share to CD4 Lymphocyte Count

Share to Cell Count

Share to Endothelial Progenitor Cells

Share to Pilot Projects

Source

Open in PubMed Open full text

Identifiers

PMID: 27658740
DOI: 10.1080/15284336.2016.1234222
PMCID: PMC5470589

Genes

KDR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study.PMID 27658740Read ↗

Cardiovascular Disease (CVD) Risk Assessment of HIV Medication Regimens using hematopoietic CD34+ progenitor cellsSemantic proximity Read ↗

Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial.Semantic proximity Read ↗

Circulating Progenitor Cells, Regenerative Capacity and Cognition: Evidence From 2 Community-Based Cohorts.Semantic proximity Read ↗

Short Communication High Risk of Endothelial Dysfunction in HIV Individuals May Result from Deregulation of Circulating Endothelial Cells and Endothelial Progenitor CellsSemantic proximity Read ↗

Linagliptin, when compared to placebo, improves CD34+ve Endothelial Progenitor Cells in Type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin, a randomized controlled trial.Semantic proximity Read ↗

Endothelial progenitor cell trafficking in human immunodeficiency virus-infected personsSemantic proximity Read ↗

Progenitor Cells, Regenerative Capacity, and CognitionSemantic proximity Read ↗

Angiogenic CD8 T cells from PWH induce Granzymes-dependent PAR1 activation promoting endothelial inflammationSemantic proximity Read ↗

Clonal Hematopoiesis Is Associated With Low CD4 Nadir and Increased Residual HIV Transcriptional Activity in Virally Suppressed Individuals With HIV.Semantic proximity Read ↗

Sex Differences in Circulating Progenitor Cells.Semantic proximity Read ↗

Association of T Cell and Macrophage Activation with Arterial Vascular Health in HIVSemantic proximity Read ↗

Mobilization of putative high-proliferative-potential endothelial colony-forming cells during antihypertensive treatment in patients with essential hypertension.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.